Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 754-760

  Dhanraj, Santhosh ^a   Manji, Arif ^a,b   Pinto, Dalila ^a   Scherer, Stephen W ^a   Favre, Helen ^c   Loh, Mignon L ^c   Chetty, Runjan ^d   Wei, Alice C ^e   Dror, Yigal ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer predisposition; Copy number alteration; Pancreatic adenocarcinoma; Shwachman Diamond syndrome

Indexed keywords

BETA CATENIN; CYCLIN D1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; UVOMORULIN;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CASE REPORT; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHWACHMAN SYNDROME; SOLID TUMOR; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; ALPHA CATENIN; BASE SEQUENCE; BONE MARROW DISEASES; DNA COPY NUMBER VARIATIONS; EXOCRINE PANCREATIC INSUFFICIENCY; GALECTINS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPOMATOSIS; MALE; PANCREATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84874975172     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24453     Document Type: Article

References (39)

1. Shwachman H. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 1964; 65: 645-663.
2. Bodian M, Sheldon W, Lightwood R. Congenital hypoplasia of the exocrine pancreas. Acta Paediatr 1964; 53: 282-293.
3. Nezelof C, Watchi M. Lipomatous congenital hypoplasia of the exocrine pancreas in children (2 cases and review of the literature). Arch Fr Pediatr 1961; 18: 1135-1172.
4. Hashmi SK, Allen C, Klaassen R, et al. Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. Clin Genet 2011; 79: 448-458.
5. Mack DR, Forstner GG, Wilschanski M, et al. Shwachman syndrome: Exocrine pancreatic dysfunction and variable phenotypic expression. Gastroenterology 1996; 111: 1593-1602.
6. Goobie S, Popovic M, Morrison J, et al. Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum Genet 2001; 68: 1048-1054.
7. Rujkijyanont P, Watanabe K, Ambekar C, et al. SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway. Haematologica 2008; 93: 363-371.
8. Watanabe K, Ambekar C, Wang H, et al. SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. Apoptosis 2009; 14: 77-89.
9. Menne TF, Goyenechea B, Sanchez-Puig N, et al. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet 2007; 39: 486-495.
10. Dror Y. Shwachman-Diamond syndrome. Pediatr Blood Cancer 2005; 45: 892-901.
11. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45-53.
12. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematol Am Soc Hematol Educ Program 2007; 2007: 29-39.
13. Singh SA, Vlachos A, Morgenstern NJ, et al. Breast cancer in a case of Shwachman Diamond syndrome. Pediatr Blood Cancer 2012; 59: 945-946.
14. Dror Y. Shwachman-Diamond syndrome: Implications for understanding the molecular basis of leukaemia. Expert Rev Mol Med 2008; 10: e38.
15. Feuk L, Marshall CR, Wintle RF, et al. Structural variants: Changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006; 15: R57-R66.
16. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-454.
17. Freeman JL, Perry GH, Feuk L, et al. Copy number variation: New insights in genome diversity. Genome Res 2006; 16: 949-961.
18. Meehan M, Melvin A, Gallagher E, et al. Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder. Genes Chromosomes Cancer 2007; 46: 587-593.
19. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209.
20. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
21. Sack JE, Kuchnir L, Demierre MF. Dermatofibrosarcoma protuberans arising in the context of Shwachman-Diamond syndrome. Pediatr Dermatol 2011; 28: 568-569.
22. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332: 494-499.
23. Crawford HC, Scoggins CR, Washington MK, et al. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002; 109: 1437-1444.
24. Lardon J, Bouwens L. Metaplasia in the pancreas. Differentiation 2005; 73: 278-286.
25. Koorstra JB, Hustinx SR, Offerhaus GJ, et al. Pancreatic carcinogenesis. Pancreatology 2008; 8: 110-125.
26. Chetty R, Serra S. Nuclear E-cadherin immunoexpression: From biology to potential applications in diagnostic pathology. Adv Anat Pathol 2008; 15: 234-240.
27. Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14: 412-418.
28. Kullmann F, Hartmann A, Stohr R, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: Results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 2011; 81: 3-8.
29. Forbes SA, Bhamra G, Bamford S, Dawson E, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008; (Supplement 57): 10.11.1-10.11.26.
30. Immervoll H, Hoem D, Kugarajh K, et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Archiv Int J Pathol 2006; 448: 788-796.
31. Chu GC, Kimmelman AC, Hezel AF, et al. Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101: 887-907.
32. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma-genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer 2006; 45: 721-730.
33. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011; 117: 2567-2576.
34. Ceccaldi R, Parmar K, Mouly E, et al. Bone marrow failure in fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012; 11: 36-49.
35. Smith DI, Zhu Y, McAvoy S, et al. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006; 232: 48-57.
36. Liang WS, Craig DW, Carpten J, et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS ONE 2012; 7: 1-20, e43192.
37. Li YJ, Meng YX, Ji XR. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2003; 2: 471-477.
38. Nobumoto A, Nagahara K, Oomizu S, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008; 18: 735-744.
39. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: Prospects for leukemia prevention. Hematol Am Soc Hematol Educ Program 2007; 2007: 40-46.